25iP-NBOMe
25iP-NBOMe is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of the hallucinogen 2C-iP. It has emerged as a rarely encountered novel designer drug1 and remains largely unresearched. Reported to be extremely potent with stimulating qualities, it may produce uncomfortable body load and potentially dangerous vasoconstriction at higher doses. Very limited information is available regarding its safety profile and pharmacological properties.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
25iP-NBOMe produces a stimulating psychedelic experience broadly typical of the NBOMe series, combining euphoria, empathy, and a sense of insight with prominent open and closed-eye visuals. The headspace involves a general shift in perception and a softening of the ego, though confusion can also occur. As with other N-benzylphenethylamines, the substance is active at sub-milligram doses and its subjective profile remains only sparsely documented.
Physical
The body experience carries a distinct stimulation with restlessness, muscle tension, and decreased appetite. Pupil dilation, sweating and chills, and difficulty sleeping are also reported.
Stimulation
Uncomfortable
Cognitive
The mental state is stimulating and euphoric, with enhanced empathy, a sense of insight, and a mild softening of the sense of self. Confusion is possible, particularly at stronger doses.
Emotional
Visual
Visual effects include brightened colors and both open and closed-eye visuals.
Tactile
Sense of touch is enhanced.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
The pharmacology of 25iP-NBOMe remains poorly characterized. Interactions with the μ-opioid receptor have been reported,2 though the nature and functional significance of this binding have not been detailed in available literature.
Pharmacokinetics
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics, 5-HT2A agonists
Harm Potential
Toxicity
May cause potentially dangerous vasoconstriction at high doses; the extreme potency of this compound increases the risk of accidental overdose leading to cardiovascular complications.
History & Culture
25iP-NBOMe emerged as a novel designer drug and was first documented in the scientific literature around 2014. Like other members of the NBOMe series, it represents an N-benzyl modification of an existing 2C-x compound—in this case, 2C-iP. The substance remains relatively obscure compared to more widely encountered NBOMe compounds such as 25I-NBOMe or 25C-NBOMe,1 with limited information available regarding its history of human use or cultural significance.
Legality
By Country
References
Source Pages
Citations
- (February 2015). Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila), 53(2), 85–92. https://doi.org/10.3109/15563650.2015.100417912
- Deventer MH, Persson M, Laus A, Pottie E, Cannaert A, Tocco G, Gréen H, & Stove CP. (2023). Off-target activity of NBOMes and NBOMe analogs at the μ opioid receptor. Archives of Toxicology, 97(5), 1367–1384. https://doi.org/10.1007/s00204-023-03465-912
- (2014). The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (SI 2014/1106). https://www.legislation.gov.uk/uksi/2014/1106/made1
- (1971). Misuse of Drugs Act 1971 — Schedule 4 (Prosecution and Punishment of Offences). https://www.legislation.gov.uk/ukpga/1971/38/schedule/41
Further Reading
Ettrup A et al. 'Structure-Activity Relationships of NBOMe 5-HT2A Agonists' Journal of Neurochemistry 2013- King LA 'New phenethylamines in Europe' Drug Testing and Analysis 2014
- Nichols DE 'Psychedelics' Pharmacological Reviews 2016
Nichols DE. ‘Psychedelics’ Pharmacol Rev 2016 (general NBOMe toxicity)- Poulie CBM et al. 'Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability' Neurochemical Research 2014
- Rickli A et al. 'Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)' Neuropharmacology 2015
- Zawilska JB, Kacela M, Adamowicz P 'NBOMes–Highly Potent and Toxic Alternatives of LSD' Frontiers in Neuroscience 2020
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25iP-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.